Scilex Holding Announces That Many National Pharmacy Chains And Independent Pharmacies Have Begun Stocking GLOPERBA, The First Oral Liquid Medicine For Prophylaxis Of Gout Flares
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding has launched GLOPERBA®, the first oral liquid medicine for the prophylaxis of gout flares, and it is now being stocked by many national and independent pharmacies. The product is priced at $595 per bottle and aims to address the growing need for gout treatment in the U.S., where the market is projected to reach $2.0 billion by 2028.
June 11, 2024 | 1:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scilex Holding has launched GLOPERBA®, the first oral liquid medicine for gout flare prophylaxis, now available in many national and independent pharmacies. This product launch could significantly boost Scilex's revenue and market presence in the growing gout treatment market.
The launch of GLOPERBA® as the first oral liquid medicine for gout flare prophylaxis is a significant milestone for Scilex. With the product now available in many pharmacies and the gout treatment market projected to grow, this could lead to increased revenue and market share for Scilex.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100